Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Immunitybio Inc (IBRX)
Immunitybio Inc (IBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,144,891
  • Shares Outstanding, K 667,705
  • Annual Sales, $ 240 K
  • Annual Income, $ -416,570 K
  • 60-Month Beta 1.24
  • Price/Sales 3,737.65
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade IBRX with:

Options Overview Details

View History
  • Implied Volatility 159.23% ( +1.66%)
  • Historical Volatility 156.94%
  • IV Percentile 76%
  • IV Rank 25.87%
  • IV High 424.99% on 10/18/23
  • IV Low 66.49% on 12/15/23
  • Put/Call Vol Ratio 0.11
  • Today's Volume 2,083
  • Volume Avg (30-Day) 6,719
  • Put/Call OI Ratio 0.42
  • Today's Open Interest 139,901
  • Open Int (30-Day) 98,877

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.18
  • Number of Estimates 1
  • High Estimate -0.18
  • Low Estimate -0.18
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.37 +39.76%
on 02/23/24
5.25 -10.29%
on 02/22/24
+1.06 (+29.04%)
since 02/01/24
3-Month
3.10 +51.94%
on 12/11/23
5.28 -10.82%
on 12/28/23
+0.93 (+24.60%)
since 12/01/23
52-Week
1.21 +289.26%
on 03/15/23
6.93 -32.03%
on 05/09/23
+2.44 (+107.49%)
since 03/01/23

Most Recent Stories

More News
Should You Still Buy the Nasdaq's Best-Performing October Stocks?

Last month's big winners were tricky to handle due to the amount of speculation investors were willing to do with them.

COMP : 3.85 (-2.53%)
GPCR : 41.24 (+1.65%)
IBRX : 4.71 (-0.42%)
OLK : 23.01 (+2.86%)
Why Shares of ImmunityBio Jumped This Week

The company's founder is spending his own money to help finance the business's efforts.

IBRX : 4.71 (-0.42%)
SHAREHOLDER ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 29, 2023 in the Class Action Filed on Behalf of ImmunityBio, Inc. (IBRX) Shareholders

/PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of ImmunityBio, Inc. (NASDAQ: IBRX)...

IBRX : 4.71 (-0.42%)
SHAREHOLDER ALERT: Levi & Korsinsky Notifies ImmunityBio, Inc.(IBRX) Investors of a Class Action Lawsuit and Upcoming Deadline

/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX) of a class action securities...

IBRX : 4.71 (-0.42%)
IBRX FINAL DEADLINE TUESDAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important August 29 Deadline in Securities Class Action - IBRX

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between May 23,...

IBRX : 4.71 (-0.42%)
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit

/PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action...

IBRX : 4.71 (-0.42%)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ImmunityBio, Inc. of Class Action Lawsuit and Upcoming Deadline - IBRX

/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX),...

IBRX : 4.71 (-0.42%)
IBRX LAWSUIT ALERT: Levi & Korsinsky Notifies ImmunityBio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX) of a class action securities...

IBRX : 4.71 (-0.42%)
IBRX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 29, 2023 in the Class Action Filed on Behalf of ImmunityBio, Inc. Shareholders

/PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of ImmunityBio, Inc. (NASDAQ: IBRX)...

IBRX : 4.71 (-0.42%)
ROSEN, A LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors with Losses to Secure Counsel Before Important August 29 Deadline in Securities Class Action - IBRX

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between May 23,...

IBRX : 4.71 (-0.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

ImmunityBio Inc. is a late-clinical-stage immunotherapy company developing therapies which drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems. ImmunityBio Inc., formerly known as NantKwest...

See More

Key Turning Points

3rd Resistance Point 5.25
2nd Resistance Point 5.14
1st Resistance Point 4.92
Last Price 4.71
1st Support Level 4.59
2nd Support Level 4.48
3rd Support Level 4.26

See More

52-Week High 6.93
Fibonacci 61.8% 4.74
Last Price 4.71
Fibonacci 50% 4.07
Fibonacci 38.2% 3.40
52-Week Low 1.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar